Controlled delivery of antisense oligonucleotides: A brief review of current strategies

Xiubo Zhao, Fang Pan, Cathy M. Holt, Andrew L. Lewis, Jian R. Lu

    Research output: Contribution to journalArticlepeer-review


    Antisense therapy has been investigated extensively over the past two decades, either experimentally for gene functional research or clinically as therapeutic agents owing to the conceptual simplicity, ease of design and low cost. The concept of this therapeutic approach is promising because short antisense oligonucleotides (ASOs) can be delivered into target cells for specific hybridisation with target mRNA, resulting in the inhibition of the expression of pathogenic genes. However, the efficient delivery of the ASO molecules into target cells remains challenging; this bottleneck together with several other technical hurdles need to be overcome before this approach becomes effective and widely adopted. A variety of vectors such as lipids, polymers, peptides and nanoparticles have been explored. This review outlines the recent advances of the non-viral ASO delivery strategies. Several recent scientific studies, including authors' contributions, have been selected to highlight the technical aspects of ASO delivery. © 2009 Informa UK Ltd All rights reserved.
    Original languageEnglish
    Pages (from-to)673-686
    Number of pages13
    JournalExpert Opinion on Drug Delivery
    Issue number7
    Publication statusPublished - Jul 2009


    • Antisense
    • Cationic lipids
    • Controlled release
    • Gene delivery
    • Liposomes
    • Microspheres
    • Nanoparticles
    • Oligonucleotides
    • Polymers
    • Surface matrices


    Dive into the research topics of 'Controlled delivery of antisense oligonucleotides: A brief review of current strategies'. Together they form a unique fingerprint.

    Cite this